Patents by Inventor Thorsten Lehmann-Lintz

Thorsten Lehmann-Lintz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS
    Publication number: 20120010185
    Abstract: The present invention relates to compounds of general formula I wherein the groups and radicals B, k, L, U, V, W, X, Y, Z, R1, R2, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
    Type: Application
    Filed: September 22, 2011
    Publication date: January 12, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Dirk STENKAMP, Stephan Georg MUELLER, Gerald Juergen ROTH, Joerg KLEY, Klaus RUDOLF, Armin HECKEL, Marcus SCHINDLER, Ralf LOTZ, Thorsten LEHMANN-LINTZ
  • MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
    Publication number: 20120004202
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R6 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: March 31, 2011
    Publication date: January 5, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: John Edward PARK, Nveed CHAUDHARY, Gerald Juergen ROTH, Armin HECKEL, Thorsten LEHMANN-LINTZ, Joerg KLEY
  • Pyridone derivates with MCH antagonistic activity and medicaments comprising these compounds
    Patent number: 8067590
    Abstract: The present invention relates to compounds of general formula I wherein the groups and radicals B, k, L, U, V, W, X, Y, Z, R1, R2, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: November 29, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Joerg Kley, Klaus Rudolf, Armin Heckel, Marcus Schindler, Ralf Lotz, Thorsten Lehmann-Lintz
  • Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
    Publication number: 20110269791
    Abstract: The present invention relates to compounds defined by Formula (I), wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11?-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.
    Type: Application
    Filed: May 12, 2009
    Publication date: November 3, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stefan Peters, Matthias Eckhardt, Bradford S. Hamilton, Frank Himmelsbach, Joerg Kley, Thorsten Lehmann-Lintz
  • CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20110217311
    Abstract: The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 8, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thorsten LEHMANN-LINTZ, Armin HECKEL, Joerg KLEY, Elke LANGKOPF, Nobert REDEMANN, Achim SAUER, Leo THOMAS, Dieter WIEDENMAYER, Matthias AUSTEN, John DANILEWICZ, Martin SCHNEIDER, Kay SCHREITER, Phillip BLACK, Wesley BLACKABY, Ian LINNEY
  • THIENOPYRIMIDINES CONTAINING A SUBSTITUTED ALKYL GROUP FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20110212103
    Abstract: The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 1, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Armin HECKEL, Frank HIMMELSBACH, Joerg KLEY, Thorsten LEHMANN-LINTZ, Norbert REDEMANN, Achim SAUER, Leo THOMAS, Dieter WIEDENMAYER, Phillip BLACK, Wesley BLACKABY, Ian LINNEY, Matthias AUSTEN, John DANILEWICZ, Martin SCHNEIDER, Kay SCHREITER
  • HETEROCYCLOALKYL-CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
    Publication number: 20110212102
    Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.
    Type: Application
    Filed: February 25, 2011
    Publication date: September 1, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thorsten LEHMANN-LINTZ, Joerg KLEY, Norbert REDEMANN, Achim SAUER, Leo THOMAS, Dieter WIEDENMAYER, Matthias AUSTEN, John DANILEWICZ, Martin SCHNEIDER, Kay SCHREITER, Phillip BLACK, Wesley BLACKABY, Ian LINNEY
  • Aryl-and Heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
    Publication number: 20110190262
    Abstract: The present invention relates to compounds defined by formula I wherein the groups R1 to R3, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11?-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity and dyslipidemia.
    Type: Application
    Filed: November 14, 2008
    Publication date: August 4, 2011
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Frank Himmelsbach, Matthias Eckhardt, Bradford S. Hamilton, Armin Heckel, Joerg Kley, Thorsten Lehmann-Lintz, Herbert Nar, Stefan Peters, Annette Schuler-Metz, Matthias Zentgraf
  • Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments
    Patent number: 7858616
    Abstract: The present invention relates to indolinone derivatives, substituted in the 6-position, of the formula in which R1 to R6 and X are as defined in Claim 1, to their tautomers, enantiomers, diastereomers, to their mixtures and to their salts, in particular their physiologically acceptable salts, which have useful pharmacological properties, in particular in inhibiting action on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, to medicaments comprising these compounds, to their use and to processes for their preparation.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: December 28, 2010
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Gerald Juergen Roth, Armin Heckel, Thorsten Lehmann-Lintz, Joerg Kley, Frank Hilberg, Jacobus C. A. Van Meel, Ulrike Tontsch-Grunt
  • Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds
    Publication number: 20100197908
    Abstract: The present invention relates to compounds of general formula I wherein the groups and radicals B, W, X, Y, Z, R1, R2, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
    Type: Application
    Filed: December 10, 2007
    Publication date: August 5, 2010
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Lehmann-Lintz, Dirk Stenkamp, Gerald Juergen Roth, Stephan Georg Mueller, Joerg Kley, Armin Heckel, Klaus Rudolf, Marcus Schindler, Ralf Lotz, Patrick Tielmann
  • 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments
    Patent number: 7759347
    Abstract: The present invention relates to new 2-benzylaminodihydropteridinones of general formula (I) wherein the groups R1 to R7, R10 and R11 have the meanings given in the claims and specification, the isomers thereof, methods of preparing these dihydropteridinones and their use as medicaments.
    Type: Grant
    Filed: January 22, 2009
    Date of Patent: July 20, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Hoffmann, Matthias Grauert, Thorsten Lehmann-Lintz, Martin Steegmaier, Flavio Solca, Norbert Redemann
  • ?-ketoamide compounds with MCH antagonistic activity
    Patent number: 7605176
    Abstract: Compounds of formula I wherein the groups and residues A, B, b, X, Y, Z, R1, R2, R3, R5a and R5b have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one amide according to the invention. As a result of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: October 20, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Gerald Juergen Roth, Philipp Lustenberger, Dirk Stenkamp, Stephan Georg Mueller, Thorsten Lehmann-Lintz, Marcus Schindler, Leo Thomas, Ralf R. H. Lotz, Marco Santagostino
  • Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
    Patent number: 7592358
    Abstract: Alkyne compounds having MCH-receptor antagonistic activity, which are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.
    Type: Grant
    Filed: April 13, 2005
    Date of Patent: September 22, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Stenkamp, Stephan Georg Mueller, Philipp Lustenberger, Thorsten Lehmann-Lintz, Gerald Juergen Roth, Klaus Rudolf, Marcus Schindler, Leo Thomas, Ralf Lotz
  • Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
    Patent number: 7592373
    Abstract: Compounds of formula (I) wherein A, B, b, W, X, Y, Z, R1, R2, and R3 have the meanings given in claim 1, pharmaceutical compositions these compounds, and methods of preventing or treating metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes using these compounds.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: September 22, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Lehmann-Lintz, Ralf R. H. Lotz, Philipp Lustenberger, Stephan Georg Mueller, Gerald Juergen Roth, Klaus Rudolf, Marcus Schindler, Dirk Stenkamp, Leo Thomas
  • INDOLINONE DERIVATIVES SUBSTITUTED IN THE 6 POSITION, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
    Publication number: 20090197876
    Abstract: The present invention relates to indolinone derivatives, substituted in the 6-position, of the formula in which R1 to R6 and X are as defined in Claim 1, to their tautomers, enantiomers, diastereomers, to their mixtures and to their salts, in particular their physiologically acceptable salts, which have useful pharmacological properties, in particular in inhibiting action on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, to medicaments comprising these compounds, to their use and to processes for their preparation.
    Type: Application
    Filed: April 10, 2009
    Publication date: August 6, 2009
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Gerald Juergen ROTH, Armin HECKEL, Thorsten LEHMANN-LINTZ, Joerg KLEY, Frank HILBERG, Jacobus C.A. VAN MEEL, Ulrike TONTSCH-GRUNT
  • Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments
    Patent number: 7547703
    Abstract: The present invention relates to indolinone derivatives, substituted in the 6-position, of the formula in which R1 to R6 and X are as defined in claim 1, to their tautomers, enantiomers, diastereomers, to their mixtures and to their salts, in particular their physiologically acceptable salts, which have useful pharmacological properties, in particular in inhibiting action on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, to medicaments comprising these compounds, to their use and to processes for their preparation.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: June 16, 2009
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Gerald Juergen Roth, Armin Heckel, Thorsten Lehmann-Lintz, Joerg Kley, Frank Hilberg, Jacobus C. A. Van Meel, Ulrike Tontsch-Grunt
  • 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments
    Publication number: 20090124628
    Abstract: The present invention relates to new 2-benzylaminodihydropteridinones of general formula (I) wherein the groups R1 to R7, R10 and R11 have the meanings given in the claims and specification, the isomers thereof, methods of preparing these dihydropteridinones and their use as medicaments.
    Type: Application
    Filed: January 22, 2009
    Publication date: May 14, 2009
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Matthias HOFFMANN, Matthias GRAUERT, Thorsten LEHMANN-LINTZ, Martin STEEGMAIER, Flavio SOLCA, Norbert REDEMANN
  • Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
    Patent number: 7524862
    Abstract: Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.
    Type: Grant
    Filed: April 13, 2005
    Date of Patent: April 28, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Stenkamp, Stephan Georg Mueller, Philipp Lustenberger, Thorsten Lehmann-Lintz, Gerald Juergen Roth, Klaus Rudolf, Marcus Schindler, Leo Thomas, Ralf Lotz
  • Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
    Patent number: 7514468
    Abstract: The present invention relates to indolinone derivatives substituted in the 6 position of general formula wherein R1 to R6 and X are defined as in claim 1, the tautomers, enantiomers, diastereomers, mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof, which have valuable pharmacological properties, in particular an inhibiting effect on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
    Type: Grant
    Filed: July 22, 2003
    Date of Patent: April 7, 2009
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Armin Heckel, Frank Hilberg, Thorsten Lehmann-Lintz, Guenter Linz, Joerg Kley, Jacobus C. A. Van Meel, Werner Rall, Gerald Juergen Roth, Peter Sieger, Ulrike Tontsch-Grunt
  • ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS
    Publication number: 20090069282
    Abstract: The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
    Type: Application
    Filed: May 15, 2008
    Publication date: March 12, 2009
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Thorsten Lehmann-Lintz, Klaus Rudolf, Philipp Lustenberger, Kirsten Arndt, Ralf R. H. Lotz, Martin Lenter